The number of vaccines on the Belarusian pharmaceutical market is constantly increasing. The Republic of Belarus takes an active position in the fight against serious infectious diseases. We participate in WHO programs to eliminate poliomyelitis, measles, acquired and congenital rubella.
Vaccines go through a complex licensing and clinical trial process. The use of vaccines is under constant control. Each case of complications after vaccination is carefully investigated. There are already 12 vaccines against dangerous infections in the National calendar of the Republic of Belarus. «Polmed» LLC arranges the supply of the most effective medicines, and also helps to bring new ones to the market, provide full support and convey information to specialists and patients.
We supply vaccines that are widespread and of great interest, because they allow you to protect yourself and reduce the risk of complications in diseases such as pneumonia, meningitis, sepsis, otitis, tick-borne encephalitis.
Our company cooperates with PFIZER H.C.P. CORPORATION. We are the exclusive distributor of Prevnar-13, TicoVac, TicoVac Junior, and Trumenba vaccines. But we are not going to stop. The main goal of «Polmed», using advanced developments in the field of vaccination, is to provide patients with the opportunity to protect themselves from serious infectious diseases and their consequences.
The pharmaceutical industry of the Republic of Belarus is developing dynamically. Over the past 10 years, more than 140 new medicines have been registered and introduced into medical practice in the country. Particular attention is paid to the development of generics for the treatment of oncological and orphan diseases. Domestic pharmacists work closely with foreign colleagues to ensure the production of safe, effective analogues of biological and biotechnological medicines.
Despite this, the level of exports is also increasing. The country regularly receives more than 1,000 types of hospital and pharmacy products that are developed abroad. «Polmed» LLC supplies several dozens of anticancer medicines, immunosuppressants, biotherapy agents and blood products, which are used in state protocols for the treatment of oncology of various origins. We work closely with manufacturers and their representatives so that patients in Belarus can receive high-quality medicines at affordable prices.
Our company supplies innovative anticancer medicines, as well as targeted therapy medicines. The therapy has proved its effectiveness where other failed. Medicines can stabilize the malignant process, prevent relapses, control the spread of metastases.
In this domain we cooperate with PFIZER H.C.P. CORPORATION, Takeda Pharmaceutical Company, Octapharma, AbbVie, Novartis International AG, Janssen Pharmaceutica N.V.
The goal of «Polmed» is to provide Belarusian patients with the opportunity to use advanced achievements in the fight against oncological diseases according to the latest protocols. We are always open for cooperation. We provide a full-fledged promotion of medicines and help to convey information to the attending physicians and patients.
Pharmacology is constantly developing, and with it the Belarusian market of pharmaceutical preparations is expanding. In recent years, there has been a tendency to increase the number of generics that are being developed by domestic specialists with the help of foreign colleagues. In terms of their properties and effectiveness, they are not inferior to the original products. However, each medicinal product has its own expiration date, and the products of foreign manufacturers continue to dominate the retail pharmaceutical market in terms of value.
«Polmed» company is engaged in the supply of pharmaceutical preparations to the Belarusian market - prescription and over-the-counter, dietary supplements. Our goal is to help manufacturers successfully bring medicines to the new market, provide information to physicians and patients, and provide full support on all issues.
We plan to expand the list of pharmaceutical preparations that we supply. Join us if you want to assess the risks of entering a new market and draw up a strategy for successful promotion.